20/20 Biolabs, Inc.
AIDX
$1.46
$0.096.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -58.43% | -2.83% | 0.00% | 35.72% | 33.33% |
| Total Depreciation and Amortization | -4.74% | -5.38% | 0.00% | -31.60% | -6.59% |
| Total Amortization of Deferred Charges | 469.19% | -- | -- | -- | -- |
| Total Other Non-Cash Items | 211.42% | 0.00% | 0.00% | -80.88% | -25.29% |
| Change in Net Operating Assets | 2.26% | 93.50% | 0.00% | 1,109.40% | -96.77% |
| Cash from Operations | -32.67% | 24.55% | 0.00% | 4.72% | 7.88% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -18.69% | 1,347.43% | 0.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | 0.00% | -12.55% | 38.02% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -22.46% | 286.13% | 0.00% | 19.27% | 38.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -198.35% | 131.82% | 0.00% | 10.88% | 15.18% |